A WVU Cancer Institute team led by Shyam Thakkar, M.D., is the first in the world to commercially use the new, FDA-approved 180° C2 Cryoballoon in the treatment of Barrett’s esophagus, a precancerous condition that can lead to esophageal cancer.
The innovative Pentax Medical device offers a novel approach to reducing the risk of cancer progression.
The 180° C2 Cryoballoon enables a highly targeted, minimally invasive cryotherapy treatment that effectively freezes and eliminates abnormal cells in the esophagus. This advanced method enhances safety and precision, providing a new tool in the fight against esophageal cancer.
“This new technology offers a significant advancement in how we can eradicate the disease. The ability to precisely target and treat abnormal cells with cryotherapy in this manner offers new possibilities for patients at risk, providing additional safe and effective treatment options,” Dr. Thakkar, director of the Advanced Center of Endoscopy at WVU Medicine and the WVU Cancer Institute, said. “I am honored to add this tool in our quest of esophageal cancer prevention.”
According to the National Institutes of Health, most Barrett’s esophagus cases are acquired and often preceded by years of gastroesophageal reflux (GERD). Barrett esophagus can be found in 5-12 percent of patients with chronic GERD symptoms.
Pentax Medical’s Cryoballoon technology represents a significant step forward in endoscopic treatments, helping physicians manage complex gastrointestinal conditions with greater efficacy. The successful use of this technology at the WVU Cancer Institute demonstrates a continued commitment to pioneering medical innovations that enhance patient outcomes.
The first patient, Rickey Harbert, 71, of Clarksburg, underwent the procedure on Oct. 15. He went home after an hour and is doing well. Thakkar said Harbert was back to normal activities the day after the procedure.
“The WVU Cancer Institute is committed to delivering the highest levels of care, combining cutting-edge research with compassionate treatment,” Hannah Hazard-Jenkins, M.D., executive chair and director of the WVU Cancer Institute, said.
“We are leading the way in cancer care through innovative therapies, groundbreaking clinical trials and a relentless dedication to improving patient outcomes for patients in West Virginia and beyond. In addition to treatment, we are also at the forefront of cancer prevention, using innovative techniques like the Cryoballoon to enhance early detection, thereby preventing progression to cancer in many instances.”
For more information on the WVU Cancer Institute, visit WVUMedicine.org/Cancer.
